Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101).
Naoya NishiokaHisao ImaiMasahiro EndoAkifumi NotsuKosei DoshitaSatoshi IgawaHiroshi YokouchiTakashi NinomiyaTakaaki TokitoSayo SodaTakasato FujiwaraTetsuhiko AsaoShinji NakamichiTakahisa KawamuraMinehiko InomataKazuhisa NakashimaKentaro ItoYasuhiro GotoYukihiro UmedaSoichi HiraiRyota UshioKeiki YokooTakayuki TakedaTomoya FukuiMasashi IshiharaTakashi OsakiSousuke KuboTakumi FujiwaraChie YamamotoTakeshi TsudaNobumasa TamuraShinobu HosokawaYusuke ChiharaSatoshi IkedaNaoki FuruyaYoshiro NakaharaSatoru MiuraHiroaki OkamotoPublished in: Targeted oncology (2024)
Osimertinib rechallenge after initial pneumonitis was associated with significantly higher recurrence rates than conventional EGFR-TKI rechallenge.